I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.

David W. Anstice net worth and biography

David Anstice Biography and Net Worth

Director of Alkermes

Mr. Anstice most recently served as Executive Vice President of Merck & Co., Inc. from 2006 to 2008 with responsibility for enterprise strategy and implementation. During separate parts of this period, he served as acting President, Global Human Health and as President of Merck’s business in Japan. From 2003 to 2006, Mr. Anstice served as President of Merck, with responsibility for Merck’s Asia Pacific businesses. In his 34 years with Merck, Mr. Anstice held a variety of positions with their worldwide ventures, including President, U.S. Human Health; President, U.S./Canada; President, Human Health, the Americas; and President, Human Health, Europe. Mr. Anstice is an Adjunct Professor at the University of Sydney Business School and serves as a member of the Board of Directors at the University of Sydney USA Foundation. He is also a non-executive Director of NeuClone Pharmaceuticals Pty. Ltd and previously served as a non-executive Director of CSL Limited.

What is David W. Anstice's net worth?: The estimated net worth of David W. Anstice is at least $2.29 million as of June 7th, 2021. Mr. Anstice owns 78,081 shares of Alkermes stock worth more than $2,286,992 as of November 7th. This net worth estimate does not reflect any other assets that Mr. Anstice may own. Learn More about David W. Anstice's net worth.
How do I contact David W. Anstice?: The corporate mailing address for Mr. Anstice and other Alkermes executives is 1 BURLINGTON ROAD CONNAUGHT HOUSE, DUBLIN L2, DUBLIN 4. Alkermes can also be reached via phone at (531) 772-8000 and via email at [email protected]. Learn More on David W. Anstice's contact information.
Has David W. Anstice been buying or selling shares of Alkermes?: David W. Anstice has not been actively trading shares of Alkermes in the last ninety days. Most recently, David W. Anstice sold 5,000 shares of the business's stock in a transaction on Monday, June 7th. The shares were sold at an average price of $24.00, for a transaction totalling $120,000.00. Following the completion of the sale, the director now directly owns 78,081 shares of the company's stock, valued at $1,873,944. Learn More on David W. Anstice's trading history.
Who are Alkermes' active insiders?: Alkermes' insider roster includes Emily Alva (Director), David Anstice (Director), Iain Brown (CFO), Shane Cooke (Director), Wendy Dixon (Director), David Gaffin (SVP), Craig Hopkinson (EVP), Blair Jackson (COO), Michael Landine (SVP), Cato Laurencin (Director), Christian Nichols (SVP), Richard Pops (CEO), and Nancy Wysenski (Director). Learn More on Alkermes' active insiders.
Are insiders buying or selling shares of Alkermes?: During the last year, insiders at the sold shares 2 times. They sold a total of 20,888 shares worth more than $601,926.33. The most recent insider tranaction occured on November, 6th when EVP Craig C Hopkinson sold 10,471 shares worth more than $309,208.63. Insiders at Alkermes own 4.9% of the company. Learn More about insider trades at Alkermes.
Information on this page was last updated on 11/6/2024.

David W. Anstice Insider Trading History at Alkermes

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
6/7/2021	Sell	5,000	$24.00	$120,000.00	78,081
9/28/2020	Sell	17,832	$16.79	$299,399.28	86,213
12/12/2018	Sell	8,787	$35.59	$312,729.33	70,000
3/3/2016	Buy	5,000	$32.87	$164,350.00	15,000

David W. Anstice Buying and Selling Activity at Alkermes

Alkermes Company Overview

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Today's Range

Now: $29.05

$28.60

$29.29

50 Day Range

MA: $27.64

$25.70

$29.29

2 Week Range

Now: $29.05

$22.06

$32.88

Volume

969,097 shs

Average Volume

1,833,214 shs

Market Capitalization

$4.70 billion

P/E Ratio

14.90

Dividend Yield

N/A

Beta

0.47

I was wrong. Dead wrong.

From Porter & Company | Ad